Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: a case report.
Staphylococcal endocarditis is potentially fatal and is now the most common cause of infective endocarditis with a mortality rate of 25-47% [Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. Ann Intern Med 1992;117:560-6]. Its treatment requires maintenance of bactericidal level of antibiotics for prolonged periods to attain a culture-negative state. Although intravenous vancomycin is currently the drug of choice for methicillin resistant Staphylococcus aureus (MRSA) endocarditis, we present a case treated successfully with oral linezolid for 4 weeks due to a lack of venous access.
Nathani
N
N
Critical Care Unit, Department of Critical Care, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK. lungdoc@doctors.org.uk
Iles
P
P
Elliott
T S J
TS
D000081:Acetamides / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001249:Asthma / Q000150:complications; D004452:Echocardiography / Q000379:methods; D004697:Endocarditis, Bacterial / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D023303:Oxazolidinones / Q000008:administration & dosage*; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid